Aldeyra Therapeutics
Biotechnology, 131 Hartwell Ave, Lexington, Massachusetts, 02421, United States, 11-50 Employees
Phone Number: 78********
Who is ALDEYRA THERAPEUTICS
Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, inst...
Read More
-
Headquarters: 131 Hartwell Ave, Lexington, Massachusetts, 02421, United States
-
Date Founded: 2004
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Todd Brady
Email
Phone
Industry: Biotechnology
SIC Code: 2836
|
NAICS Code: 541714 |
Show More
Does something look wrong? Fix it. | View contact records from ALDEYRA THERAPEUTICS
Aldeyra Therapeutics Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Aldeyra Therapeutics
Answer: Aldeyra Therapeutics's headquarters are located at 131 Hartwell Ave, Lexington, Massachusetts, 02421, United States
Answer: Aldeyra Therapeutics's phone number is 78********
Answer: Aldeyra Therapeutics's official website is https://aldeyra.com
Answer: Aldeyra Therapeutics's revenue is $10 Million to $25 Million
Answer: Aldeyra Therapeutics's SIC: 2836
Answer: Aldeyra Therapeutics's NAICS: 541714
Answer: Aldeyra Therapeutics has 11-50 employees
Answer: Aldeyra Therapeutics is in Biotechnology
Answer: Aldeyra Therapeutics contact info: Phone number: 78******** Website: https://aldeyra.com
Answer: Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month